ClinicalTrials.gg
RecruitingNCT04835584Updated Mar 21, 2022

KRT-232 and TKI Study in Chronic Myeloid Leukemia

A Phase 1/2 interventional study of KRT-232 and Dasatinib in Chronic Myeloid Leukemia, sponsored by Kartos Therapeutics, Inc.. Recruiting at 26 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-21.

Sponsored by Kartos Therapeutics, Inc. (part of Ipsen) · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
109
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 517 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States — 46 open to participants now, 77 under way, 4 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States.

Planned enrollment
86th of 449
109 · median 36
Started
2021
with 13 others
Phase 1/2
55 of 517
3 open now
Primary completion
2024-12
later than 10 of 76 live
Registered
461st of 517
by date

Among the 517 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States, this one is the 86th largest by planned enrollment of the 449 interventional ones that give a count, is one of 14 that started in 2021, is one of 55 in phase 1/2, reaches primary completion later than 10 of the 76 other live ones, and was the 461st registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

895 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 105 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

46 of the 517 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 46 (61%) set no upper age limit and 19 (25%) stop at 75 or younger; 19 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 517 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States, or all of them as a file.
02

Study summary

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI).

This study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML (CML-CP) and accelerated phase (CML-AP) who have failed TKI treatments.

03

Conditions studied

  • Chronic Myeloid Leukemia

Keywords

  • navtemadlin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Phase 1b and Phase 2 Arms A and B: Documented TP53wt, Ph+, BCR-ABL+ CML-CP
  • Phase 2 Arm C ONLY: Documented TP53wt, Ph+, BCR-ABL+ CML-AP
  • Subject is resistant () and/or intolerant to at least 1 prior TKI.
  • Adults ≥ 18 years of age.
  • performance status of 0 to 2
  • Adequate hematologic, hepatic, and renal functions

Exclusion criteria

Exclusion Criteria:

  • Phase 1b and Phase 2 Arms A and B: Documented Ph+, BCR-ABL+ CML-AP
  • Documented Ph+, BCR-ABL+ CML-BC
  • Known T315I mutation.
  • Prior treatment with MDM2 antagonist therapies.
  • Intolerance to current TKI therapy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
109 participants (estimated)

Study arms

  • Experimental
    Part 1, KRT-232 combined with TKI (Dasatinib or Nilotinib) in patients with CML-CP

    KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. TKI (dasatinib or nilotinib) will be administered orally, per locally prescribed dose and schedule.

    Drug: KRT-232 · Drug: Dasatinib · Drug: Nilotinib

  • Experimental
    Part 2, Arm A (KRT-232 combined with Dasatinib in patients with CML-CP)

    KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Dasastinib will be administered orally, per locally prescribed dose and schedule.

    Drug: KRT-232 · Drug: Dasatinib

  • Experimental
    Part 2, Arm B (KRT-232 combined with Nilotinib in patients with CML-CP)

    KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Nilotinib will be administered orally, per locally prescribed dose and schedule.

    Drug: KRT-232 · Drug: Nilotinib

  • Experimental
    Part 2, Arm C (KRT-232 combined with Dasatinib or Nilotinib in patients with CML-AP)

    KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Dasatinib or Nilotinib will be administered orally, per locally prescribed dose and schedule.

    Drug: KRT-232 · Drug: Dasatinib · Drug: Nilotinib

Interventions

  • DrugNavtemadlinStudies of NavtemadlinNavtemadlin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.

  • Dasatinib is a Tyrosine Kinase Inhibitor anticancer drug taken by mouth.

    Also known as: Dasatinib Zentiva

  • Nilotinib is an Tyrosine Kinase Inhibitor anticancer drug taken by mouth.

    Also known as: Tasigna

06

What researchers measure

Primary outcomes

  1. Part 1: Maximum tolerated dose (MTD)/maximum administered dose (MAD) of KRT-232

    DLTs will be used to establish the MTD/MAD of KRT-232 in combination with dasatinib or nilotinib

    Time frame: 28 Days

  2. Part 2, Arm A and B: Major molecular response (MMR) rate

    The proportion of subjects who achieved complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR) according to modified ELN criteria

    Time frame: 6 months

  3. Part 2, Arm C: Major hematological response (MaHR) rate

    The proportion of subjects who achieved MaHR according to modified ELN criteria

    Time frame: 6 months

Secondary outcomes

  1. CCyR rate

    The proportion of subjects who achieved CCyR or PCyR according to modified ELN criteria in Arms A and B

    Time frame: 12 months

  2. MCyR rate

    The proportion of subjects who achieved CCyR or PCyR according to modified ELN criteria in Arm C

    Time frame: 47 months

  3. Duration of response

    DOR (Kaplan-Meier estimate) defined as the time from first observation of response to progression/relapse or death, whichever comes first

    Time frame: 47 months

  4. Rate of complete hematologic response (CHR)

    The proportion of subjects who achieve a CHR according to modified ELN criteria in Arms A and B

    Time frame: 47 months

  5. Progression-free survival (PFS) in each Arm

    PFS is defined as the time from the first treatment dose date to progression/relapse or death, whichever comes first

    Time frame: 47 months

  6. Overall survival (OS) in each Arm

    OS is defined as the time from the first treatment dose date to death from any cause

    Time frame: 47 months

07

Study locations

26 of 26 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Dec 2024, 43 months after the start.

Of 27 phase 1/2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 56 and three quarters within 94. This study's planned 43 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2021
First posted
Apr 8, 2021
StartActual
May 7, 2021
Primary completionEst.
Dec 31, 2024
CompletionEst.
Jun 30, 2026
Last update
Mar 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04835584
Responsible party
Sponsor
First posted
Apr 8, 2021
Start date
May 7, 2021
Primary completion
Dec 31, 2024 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Mar 21, 2022

Study contacts

John Mei
Contact
jmei@kartosthera.com
650-542-0136

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion